St. John'S Wort
drugOn this page
Also known as Chase-devil wholeCommon st johnswort flowering topCommon st johnswort wholeCommon st. john's wort herbCommon st. john's wort wholeCommon st. johnswort wholeEola-weed wholeGoat-weed wholeGuanyejinsitaoHyperici herbaHyperici perforati herbaHypericumHypericum perforatumHypericum perforatum extractHypericum perforatum l.Klamath weed flowering topKlamath weed wholeKlamath-weed wholeKlamathweed flowering topKlamathweed whole
Summary
St. John’S Wort (CHEMBL2108102) is a phase-3 clinical-stage unknown (ATC N06AX25); indicated across 11 conditions including raynaud disease and head and neck cancer.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Unknown
- ATC class: N06AX25
- Indications: 11 conditions
- Clinical trials: 26
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL2108102 |
| Name | St. John’S Wort |
| Type | Unknown |
| Max phase | 3 |
| ATC | N06AX25 |
Also known as: Chase-devil whole, Common st johnswort flowering top, Common st johnswort whole, Common st. john’s wort herb, Common st. john’s wort whole, Common st. johnswort whole, Eola-weed whole, Goat-weed whole, Guanyejinsitao, Hyperici herba, Hyperici perforati herba, Hypericum
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
11 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| Raynaud disease | 3 | MONDO:0008364 | EFO:1001145 |
| head and neck cancer | 3 | MONDO:0005627 | EFO:0006859 |
| kidney neoplasm | 3 | MONDO:0021163 | EFO:0003865 |
| male reproductive organ cancer | 3 | MONDO:0005836 | EFO:0007355 |
| breast neoplasm | 3 | MONDO:0021100 | MONDO:0007254 |
| depressive disorder | 3 | MONDO:0002050 | MONDO:0002050 |
| irritable bowel syndrome | 2 | MONDO:0005052 | EFO:0000555 |
| nicotine dependence | 2 | MONDO:0008575 | EFO:0003768 |
| attention deficit-hyperactivity disorder | 2 | MONDO:0007743 | EFO:0003888 |
2 further indication records had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 26.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 7 |
| PHASE3 | 6 |
| PHASE4 | 5 |
| PHASE2 | 5 |
| PHASE1 | 3 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00006395 | PHASE4 | COMPLETED | Drug Interaction Study of Tegretol (Carbamazepine) and St. John’s Wort in Normal Volunteers |
| NCT00027014 | PHASE4 | COMPLETED | Herb-Opioid Interactions |
| NCT00131885 | PHASE4 | COMPLETED | Effects of St. John’s Wort on the Oral Contraceptive Hormone Levonorgestrel |
| NCT00557427 | PHASE4 | TERMINATED | Hypericum vs Fluoxetine for Mild to Moderate Adolescent Depression |
| NCT02862236 | PHASE4 | COMPLETED | The Acute Effect of Hypericum Perforatum on Short-Term Memory in Healthy Adults |
| NCT00005805 | PHASE3 | COMPLETED | St. John’s Wort in Relieving Fatigue in Patients Undergoing Chemotherapy or Hormone Therapy for Cancer |
| NCT00041171 | PHASE3 | WITHDRAWN | Docetaxel and St. John’s Wort in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery |
| NCT00066859 | PHASE3 | COMPLETED | Sertraline Compared With Hypericum Perforatum (St.John’s Wort) in Treating Depression |
| NCT00222365 | PHASE3 | TERMINATED | Homeopathy Assessment in Terms of the Consumption of Analgesics After Knee Ligamentoplasty |
| NCT00351117 | PHASE3 | COMPLETED | St. John’s Wort in the Treatment of Raynaud’s Phenomenon |
| NCT02840331 | PHASE3 | UNKNOWN | Pilot Study on Intra-abdominal Photodynamic Diagnosis in Peritoneal Carcinosis |
| NCT00035412 | PHASE2 | COMPLETED | St. John’s Wort Versus Placebo in Social Phobia |
| NCT00035438 | PHASE2 | COMPLETED | St. John’s Wort Vs. Placebo in Obsessive-Compulsive Disorder. |
| NCT00100295 | PHASE2 | COMPLETED | Herbal Treatment for Attention Deficit Hyperactivity Disorder (ADHD) |
| NCT00110136 | PHASE2 | TERMINATED | St. John’s Wort in Relieving Hot Flashes in Postmenopausal Women With Non-Metastatic Breast Cancer |
| NCT00587860 | PHASE2 | COMPLETED | A Placebo-Controlled Trial of St. John’s Wort for Irritable Bowel Syndrome |
| NCT01663922 | PHASE1 | COMPLETED | Boceprevir and Ucalm (St John’s Wort) |
| NCT01726764 | PHASE1 | COMPLETED | Interaction Between St John’s Wort and Metformin? |
| NCT01921881 | PHASE1 | COMPLETED | Does the Natural Medicinal Plant St John’s Wort Affect the Glucose Tolerance in Healthy Individuals |
| NCT00001919 | Not specified | COMPLETED | Neuroimaging of St. John’s Wort-Induced Changes of Serotonin Metabolism in Normal Subjects |
| NCT00026013 | Not specified | COMPLETED | Effects of St. John’s Wort on the Effectiveness of Oral Contraceptives |
| NCT00048815 | Not specified | COMPLETED | Drug Therapy to Treat Minor Depression |
| NCT01258504 | Not specified | COMPLETED | Influence of CYP3A4-induction by St. John’s Wort on the Steady State Pharmacokinetics of Bosentan |
| NCT01311362 | Not specified | COMPLETED | Influence of Cytochrome CYP3A4-induction by St. John’s Wort on the Steady State Pharmacokinetics of Ambrisentan |
| NCT01330589 | Not specified | WITHDRAWN | Pharmacodynamic Study on Efficacy of Clopidogrel With St. John’s Wort |
| NCT05477472 | Not specified | COMPLETED | Low Dose St John’s Wort for Depression |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).